A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

NCT01917019 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Remittent Progressive
Multiple Sclerosis, Primary Progressive
Relapsing-Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Multiple Sclerosis

Interventions

DRUG: Placebo
DRUG: BIIB041 (fampridine)

Sponsor

Biogen